Equities

Phreesia Inc

Phreesia Inc

Actions
Health CareHealth Care Providers
  • Price (USD)19.88
  • Today's Change0.88 / 4.63%
  • Shares traded105.11k
  • 1 Year change+27.35%
  • Beta0.9579
Data delayed at least 15 minutes, as of Nov 22 2024 20:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy5
Outperform10
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 14 analysts offering 12 month price targets for Phreesia Inc have a median target of 29.50, with a high estimate of 34.00 and a low estimate of 23.00. The median estimate represents a 55.26% increase from the last price of 19.00.
High78.9%34.00
Med55.3%29.50
Low21.1%23.00

Earnings history & estimates in USD

On Sep 04, 2024, Phreesia Inc reported 2nd quarter 2025 losses of -0.31 per share. This result exceeded the -0.36 consensus loss of the 12 analysts covering the company and exceeded last year's 2nd quarter results by 8.82%.
The next earnings announcement is expected on Dec 09, 2024.
Average growth rate-3.19%
Phreesia Inc reported annual 2024 losses of -1.17 per share on Mar 14, 2024.
Average growth rate-151.85%
More ▼

Revenue history & estimates in USD

Phreesia, Inc. had 2nd quarter 2025 revenues of 102.12m. This bettered the 101.70m consensus of the 16 analysts covering the company. This was 21.79% above the prior year's 2nd quarter results.
Average growth rate+4.47%
Phreesia, Inc. had revenues for the full year 2024 of 356.30m. This was 26.84% above the prior year's results.
Average growth rate+30.29%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.